Market Indices
Sector Heatmap
IMMX — Immix Biopharma, Inc. Common Stock
NasdaqImmix Biopharma, Inc. Common Stock
- O
- 10.35
- H
- 10.37
- L
- 9.48
- V
- 2.55M
IMMX — Latest News & Headlines
20 StoriesImmix plans to use about $117 million for treatment development and company operations - Stock Titan
Immix plans to use about $117 million for treatment development and company operations Stock Titan
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock - Stocktwits
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock Stocktwits
Immix Biopharma Closes $125 Million Stock Offering - Yahoo Finance
Immix Biopharma Closes $125 Million Stock Offering Yahoo Finance
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering - Quiver Quantitative
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering Quiver Quantitative
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock GlobeNewswire
Immix posts new trial data for AL amyloidosis drug (IMMX) - Seeking Alpha
Immix posts new trial data for AL amyloidosis drug (IMMX) Seeking Alpha
Immix Biopharma prices $125M stock offering - TradingView
Immix Biopharma prices $125M stock offering TradingView
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth - Simply Wall Street
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth Simply Wall Street
Immix Biopharma closes $117.1m stock offering - Investing.com
Immix Biopharma closes $117.1m stock offering Investing.com
Immix Biopharma Closes $125 Million Stock Offering - marketscreener.com
Immix Biopharma Closes $125 Million Stock Offering marketscreener.com
San Francisco will host Immix Biopharma’s presentation Jan. 11–14. - Stock Titan
San Francisco will host Immix Biopharma’s presentation Jan. 11–14. Stock Titan
A Quick Look at Today's Ratings for Immix Biopharma(IMMX.US), With a Forecast Between $24 to $30 - Moomoo
A Quick Look at Today's Ratings for Immix Biopharma(IMMX.US), With a Forecast Between $24 to $30 Moomoo
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock GlobeNewswire
All 25 new patients had a complete response or tested negative for remaining disease - Stock Titan
All 25 new patients had a complete response or tested negative for remaining disease Stock Titan
Needham maintains Buy rating on Immix Biopharma, $30 price target - TradingView
Needham maintains Buy rating on Immix Biopharma, $30 price target TradingView
Transcript : Immix Biopharma, Inc. - Shareholder/Analyst Call - marketscreener.com
Transcript : Immix Biopharma, Inc. - Shareholder/Analyst Call marketscreener.com
Immix Biopharma prices $125M stock offering at $11 per share - Investing.com India
Immix Biopharma prices $125M stock offering at $11 per share Investing.com India
Citizens reiterates Immix Biopharma stock rating on trial data By Investing.com - Investing.com India
Citizens reiterates Immix Biopharma stock rating on trial data By Investing.com Investing.com India
Needham initiates coverage on Immix Biopharma with Buy rating - scanx.trade
Needham initiates coverage on Immix Biopharma with Buy rating scanx.trade
Immix Biopharma reports promising interim Phase 2 results - TipRanks
Immix Biopharma reports promising interim Phase 2 results TipRanks